KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121,781 | +17.7% | 7,011 | -4.6% | 0.00% | – |
| Q2 2023 | $103,502 | +25.4% | 7,351 | -4.2% | 0.00% | – |
| Q1 2023 | $82,561 | -7.8% | 7,673 | +28.3% | 0.00% | – |
| Q4 2022 | $89,565 | -18.6% | 5,979 | -30.1% | 0.00% | -100.0% |
| Q3 2022 | $110,000 | +32.5% | 8,549 | 0.0% | 0.00% | – |
| Q2 2022 | $83,000 | +16.9% | 8,549 | +19.3% | 0.00% | – |
| Q1 2022 | $71,000 | -15.5% | 7,164 | 0.0% | 0.00% | – |
| Q4 2021 | $84,000 | +300.0% | 7,164 | +290.0% | 0.00% | – |
| Q3 2021 | $21,000 | -19.2% | 1,837 | 0.0% | 0.00% | – |
| Q2 2021 | $26,000 | -23.5% | 1,837 | 0.0% | 0.00% | – |
| Q1 2021 | $34,000 | +6.2% | 1,837 | 0.0% | 0.00% | – |
| Q4 2020 | $32,000 | +14.3% | 1,837 | 0.0% | 0.00% | – |
| Q3 2020 | $28,000 | – | 1,837 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |